医疗科技机器人研发商Wandercraft完成7500万美元D轮融资，用于加速AI驱动机器人技术的全球发展-动脉网

Wandercraft announces Series D Round, bringing $75M in total funding secured for global acceleration of AI-powered robotics

vcaonline 等信源发布 2025-06-11 23:46



可切换为仅中文







Wandercraft announces Series D Round, bringing $75M in total funding secured for global acceleration of AI-powered robotics

Wandercraft 宣布完成 D 轮融资，共筹集 7500 万美元，用于加速人工智能机器人技术的全球发展。

Clinical progress, industrial partnerships, and global recognition drive momentum in rehabilitation, personal mobility, and humanoid robotics.

临床进展、产业合作和全球认可推动了康复、个人移动性和人形机器人技术的发展势头。

New agreement with Renault Group accelerates commercialization and advances Wandercraft’s global robotics footprint.

与雷诺集团的新协议加速了商业化进程，并扩大了Wandercraft的全球机器人足迹。

NEW YORK, June 11, 2025-- Wandercraft, the global leader in self-balancing robotic mobility systems, today announced that it has secured $75 million funding and financing as part of its Series D round, with major contributions from Renault Group, PSIM fund, managed on behalf of the French State by Bpifrance as part of the France 2030 plan, Teampact Ventures and Quadrant Management.

纽约，2025年6月11日——全球自平衡机器人移动系统领导者Wandercraft今日宣布，已在D轮融资中获得7500万美元的资金支持，主要贡献者包括雷诺集团、由法国国家代表Bpifrance管理的PSIM基金（作为法国2030计划的一部分）、Teampact Ventures和Quadrant Management。

This influx of capital arrives during a time of rapid growth, increased global visibility, and product innovation in clinical, consumer, and industrial robotics..

这笔资金的涌入正值临床、消费和工业机器人领域快速增长、全球关注度提升以及产品创新之际。

The new funding will help propel Wandercraft into its next phase of growth: bringing Eve, the world’s first self-balancing personal exoskeleton, to market as early as 2026; expanding clinical adoption of its flagship rehabilitation system, Atalante X; and developing and deploying Calvin-40, its humanoid robot..

新资金将帮助Wandercraft迈入下一个增长阶段：最早于2026年将全球首款自平衡个人外骨骼Eve推向市场；扩大其旗舰康复系统Atalante X的临床应用；并开发和部署其人形机器人Calvin-40。

'The momentum we’ve achieved over the past few years is extraordinary,” said Matthieu Masselin, CEO and Co-founder of Wandercraft. “We’ve expanded globally, launched pivotal clinical trials, readied the commercialization of Eve, our personal exoskeleton, and entered a landmark partnership with Renault Group.

“我们在过去几年中取得的进展是非凡的，”Wandercraft首席执行官兼联合创始人马修·马瑟兰表示。“我们已经在全球扩展，启动了关键的临床试验，准备将我们的个人外骨骼Eve商业化，并与雷诺集团达成了一个里程碑式的合作伙伴关系。

This funding allows us to continue our mission of transforming how people live, move, and work across rehabilitation, home environments, and soon on factory floors.”.

这笔资金使我们能够继续我们的使命，即改变人们在康复、家庭环境以及不久的将来在工厂车间的生活、行动和工作方式。

The news comes off the back of Wandercraft’s announcement with Renault Group, whereby the car manufacturer now has a minority stake ownership and a strategic partnership with Wandercraft. The partnership brings Renault Group’s industrial expertise to scale up production of Wandercraft’s exoskeletons and industrial robots, laying the groundwork for cost-efficient scaling of Eve and the broader Calvin humanoid family.

该消息是在Wandercraft与雷诺集团宣布合作之后发布的，根据合作协议，这家汽车制造商现在拥有Wandercraft的少数股权，并与其建立了战略合作伙伴关系。此次合作将雷诺集团的工业专业知识引入Wandercraft外骨骼和工业机器人的生产规模扩大，为Eve以及更广泛的Calvin人形机器人系列的成本高效扩展奠定了基础。

Renault Group is also Wandercraft’s first commercial partner and customer of Calvin-40, named for its development time of just 40 days..

雷诺集团也是 Wandercraft 的第一个商业合作伙伴和 Calvin-40 的客户，Calvin-40 因其仅 40 天的开发时间而得名。

Calvin-40 is an industrial-grade robot intended for physically demanding tasks and the first humanoid robot developed by a European company. Calvin-40's rapid development was made possible by using Wandercraft’s rapid development process and existing leading-edge robotics platform integrated with NVIDIA Isaac technologies, including the NVIDIA Isaac GR00T N1 foundation model and the NVIDIA Jetson edge AI platform..

Calvin-40 是一款工业级机器人，专为对体力要求高的任务设计，也是欧洲公司开发的首款人形机器人。Calvin-40 的快速开发得益于 Wandercraft 的快速开发流程及其现有的尖端机器人平台，并集成了 NVIDIA Isaac 技术，包括 NVIDIA Isaac GR00T N1 基础模型和 NVIDIA Jetson 边缘 AI 平台。

Looking ahead, the Series D funding will accelerate:

展望未来，D轮融资将加速：

• Commercial deployment of Eve, the personal exoskeleton, in home and outdoor environments.

• Eve个人外骨骼在家庭和户外环境中的商业部署。

• A new phase of growth and support for Atalante X.

• 阿塔兰特X迎来增长与支持的新阶段。

• Industrial development and rollout of Calvin-40 and the broader Calvin humanoid family.

• 工业发展和推出Calvin-40及更广泛的Calvin人形家族。

Paul-François Fournier, Executive Director of Bpifrance Innovation said, “We are delighted to renew our support for Wandercraft, which has been supported by the State with Bpifrance since 2017. This Series D alongside Renault Group will enable the company to accelerate the industrial deployment of its unique robotics technology and make the Eve exoskeleton accessible to as many people as possible.

法国公共投资银行创新执行总监保罗-弗朗索瓦·富尼耶表示：“我们很高兴能够再次支持自2017年以来一直得到国家和法国公共投资银行支持的Wandercraft。此次D轮融资与雷诺集团共同进行，将使该公司能够加速其独特机器人技术的工业部署，并尽可能让更多人使用Eve外骨骼。”

Access to health and mobility for all is indeed a strategic focus supported by the French State through the France 2030 plan.”.

健康和行动能力的普及确实是法国政府通过法国2030计划支持的战略重点。

Today’s news follows a period of major growth since the company raised its Series C round of $45 million, led by Quadrant Management, which fueled U.S. commercial expansion and helped drive a tenfold increase in revenues. Other participants in the Series D round include LBO France, Mutuelles Impact – Managed by XAnge, Cemag Invest, Martagon Capital, and AG2R LA MONDIALE..

今天的新闻是在该公司完成由Quadrant Management领投的4500万美元C轮融资后发布的，这笔资金推动了美国商业扩张，并帮助收入增长了十倍。参与D轮融资的其他投资者包括LBO France、Mutuelles Impact – 由XAnge管理、Cemag Invest、Martagon Capital和AG2R LA MONDIALE。

Wandercraft’s momentum comes from its dedication to restoring independence through self-balancing, hands-free robotic systems that allow upright movement without crutches or walkers. The technology is powered by AI and has been life-tested, refined through billions of simulations and tens of millions of real-world steps..

Wandercraft的驱动力来自于其致力于通过自我平衡、免提机器人系统来恢复人们的独立性，这些系统能够让使用者无需拐杖或助行器即可直立行走。这项技术由人工智能驱动，并经过了实际生活的检验，通过数十亿次模拟和数千万次真实世界的步伐不断优化。

The result is a growing list of industry firsts and clinical achievements:

结果是越来越多的行业首创和临床成果：

Clinical Innovation, Powered by AI

临床创新，由人工智能驱动

• Received its first FDA clearance for rehabilitation exoskeleton Atalante X for stroke followed by a second FDA clearance in less than a year, then expanding its use in U.S. hospitals and clinics.

• 其康复外骨骼Atalante X首次获得FDA批准用于中风治疗，不到一年又获得第二次FDA批准，随后在美国医院和诊所的使用范围逐步扩大。

• Launched the world’s first clinical trial of a self-balancing personal exoskeleton, Eve, designed to help individuals with severe mobility impairments walk hands-free at home and in their communities.

• 推出了全球首个自我平衡个人外骨骼Eve的临床试验，该设备旨在帮助严重行动障碍者在家中和社区内实现免手操作行走。

• Deployed Atalante X in more than 100 hospitals and rehabilitation centers globally, including the Kessler Foundation, the Villa Beretta Rehabilitation Research Innovation Institute, and Vivantes Klinikum Spandau and Schön Klinik.

• 在全球超过100家医院和康复中心部署了Atalante X，包括凯斯勒基金会、Villa Beretta康复研究创新研究所、Vivantes Spandau医院和Schön诊所。

• Evaluated in more than 20 clinical studies; key findings include meaningful improvements in walking speed, balance, independence, and postural control – often accompanied by perception of reduced pain, reduced spasticity, and increased muscle strength.

• 在20多项临床研究中进行评估；主要发现包括步行速度、平衡、独立性和姿势控制方面有显著改善——通常伴随着疼痛减轻、痉挛减少和肌肉力量增强的感受。

• Enabled 2,500 people with mobility disabilities to take more than 14 million steps to date, rediscovering the freedom of upright movement once considered out of reach.

• 迄今为止，已帮助2500名行动障碍人士迈出超过1400万步，重新体验了曾经被认为遥不可及的直立行走自由。

Rehabilitation Access in the Heart of New York

纽约市中心的康复通道

• Opened “Walk in New York by Wandercraft,” the first walk center to offer regular exoskeleton walking sessions for people with mobility disabilities with conditions such as stroke and SCI.

• 开设了“纽约漫步 by Wandercraft”，这是首家为中风和脊髓损伤等行动障碍人士提供定期外骨骼步行训练的步行中心。

• The facility sits within Cure®, a healthcare innovation campus in New York City, which also houses Wandercraft’s U.S. headquarters.

该设施位于纽约市的医疗创新园区Cure®内，该园区还设有Wandercraft的美国总部。

• The company intends to establish the center as the first regional hub for Eve’s deployment ahead of its anticipated U.S. launch in 2026.

• 该公司计划在2026年Eve预计在美国推出之前，将该中心设立为Eve部署的第一个区域枢纽。

Product Innovation and Recognition

产品创新与认可

• Showcased personal exoskeleton Eve at the 2024 Olympic and Paralympic Torch Relay, symbolizing a new global standard in mobility technology.

• 在2024年奥运会和残奥会火炬接力中展示了个人外骨骼Eve，象征着移动技术的新全球标准。

• Featured by NVIDIA at CES 2025 and their annual technology conference NVIDIA GTC, the “Super Bowl of AI”, recognizing Wandercraft’s use of NVIDIA’s state-of-the-art technology and physical AI to enable autonomous, hands-free walking.

• Wandercraft因使用NVIDIA最先进的技术和物理AI实现自主、免提行走，而在2025年CES展和NVIDIA年度技术大会GTC（“AI领域的超级碗”）上被NVIDIA重点介绍。

• Honored by SXSW with a 2025 Innovation Award in the Artificial Intelligence (AI) category for its robotic exoskeleton, which represents one of the most transformative advancements in technology.

• 其机器人外骨骼在人工智能（AI）类别中荣获2025年SXSW创新奖，代表了技术领域最具变革性的进步之一。

• Joined the FT120 Index, France’s highest honor for startups, recognizing Wandercraft as a global leader in the field of robotics.

• 加入了法国初创企业最高荣誉的FT120指数，认可Wandercraft作为机器人领域的全球领导者。

Wandercraft invites individuals to learn more about its ongoing clinical trial for Eve, the personal exoskeleton. The study evaluates real-world usability, focusing on ease of movement, endurance, and integration into daily life. Adults aged 18 and older with complete or incomplete motor SCI (at or above T6) may be eligible to participate, provided they have – or can secure – a physically able companion for support.

Wandercraft 邀请个人了解更多关于其正在进行的个人外骨骼 Eve 的临床试验。该研究评估现实世界的可用性，重点关注运动的便利性、耐力以及融入日常生活的能力。年龄在 18 岁及以上的完全或不完全运动性脊髓损伤（T6 或以上）成人可能符合参与条件，前提是有或能够确保有一位身体健全的同伴提供支持。

To inquire or apply, email clinicaltrials@wandercraft.health..

要查询或申请，请发送电子邮件至 clinicaltrials@wandercraft.health。

Wandercraft is growing, and we’re seeking curious, mission-driven individuals to join our team. If you're passionate about shaping the future of mobility and tackling complex robotics challenges, check out our current openings, including roles in robot control, machine learning, customer care, and software leadership.

Wandercraft正在成长，我们正在寻找充满好奇心、以使命为导向的人才加入我们的团队。如果你热衷于塑造移动性的未来并解决复杂的机器人挑战，请查看我们当前的职位空缺，包括机器人控制、机器学习、客户关怀和软件领导等职位。

Contribute your expertise and help us create technology that moves the world..

贡献您的专业知识，帮助我们创造推动世界发展的技术。

About Wandercraft

关于Wandercraft

Wandercraft is a robotics company on a mission to restore mobility and expand what’s possible through self-balancing, AI-powered systems. Founded in 2012, Wandercraft is globally recognized for creating the world’s first self-balancing walking exoskeleton, Atalante X, which is used in more than 100 rehabilitation centers across four continents to assist individuals with disabilities in taking more than a million steps each month..

Wandercraft是一家机器人公司，致力于通过自平衡、人工智能驱动的系统恢复行动能力并拓展可能性。公司成立于2012年，凭借创造全球首款自平衡行走外骨骼Atalante X而广受认可。该设备已在四大洲的100多家康复中心投入使用，每月帮助残障人士迈出超过一百万步。

Building on over a decade of real-world experience and a proprietary neural network trained on billions of steps, Wandercraft is now bringing mobility beyond clinical settings. Its personal-use exoskeleton, Eve, is designed to assist wheelchair users in standing and walking in everyday life. Additionally, with the launch of the Calvin family of autonomous humanoid robots, Wandercraft is expanding its platform to support industrial and assistive tasks – relieving workers from hazardous labor and aiding caregivers in their daily activities..

基于十多年的真实世界经验以及在数十亿步态数据上训练的专有神经网络，Wandercraft现在正将移动能力扩展到临床环境之外。其个人使用的外骨骼Eve旨在帮助轮椅使用者在日常生活中站立和行走。此外，随着Calvin系列自主人形机器人的推出，Wandercraft正在扩展其平台以支持工业和辅助任务——使工人免于危险劳动，并帮助护理人员完成日常工作。

With more than 30 patents and a deeply human mission, Wandercraft believes that everyone should have the chance to move freely – and that robotics should connect with people where they are, with reliability, responsiveness, and purpose. Learn more at wandercraft.eu.

拥有 30 多项专利和深刻的人性化使命，Wandercraft相信每个人都应该有自由行动的机会——机器人技术应以可靠性、响应性和目的性与人们当前的需求相连接。欲了解更多信息，请访问 wandercraft.eu。

Contact:

联系：

WANDERCRAFT PRESS CONTACT

WANDERCRAFT 媒体联系人

Lilly Kofler

莉莉·科夫勒

+1 954-292-8187

lilly.kofler@wandercraft.health

莉莉·科夫勒@wandercraft.health

Jean-Louis Constanza

让-路易·康斯坦萨